226 0 Kommentare DEINOVE is the Regional Winner of the ‘PME Bougeons-Nous’ Awards in the ‘Creative Business’ Category

Regulatory News:

DEINOVE (Euronext Growth Paris: ALDEI), a biotech company that discovers, develops and produces high-value compounds from rare bacteria, notably from the Deinococcus genus, announces that is has won last night the RMC 9^th ‘PME Bougeons nous’ awards for Occitanie region in the ‘Creative Business’ category.

For 9 years, RMC ‘PME Bougeons-nous’ awards have been rewarding the dynamism, willingness, and enthusiasm of SMEs in all French regions. Four regional ceremonies were held from September 11 to 27 in Lille, Nantes, Lyon, and Montpellier. The applications of the regional award-winning SMEs will then be presented to the national jury of the ‘PME Bougeons-nous’ awards which will meet on Tuesday, October 2 in Paris. The jury, chaired by Jean-Jacques Bourdin, will elect the 6 national winners and will unveil them at the awards ceremony on Wednesday, October 17.

This contest is intended to distinguish different SMEs in 6 categories. The ‘Creative Business’ award retributes SMEs basing their development strategy on an innovative idea, such as a new technology, or a new manufacturing process.

"We are very proud of this “Creative Business” Award, which rewards our radical innovation approach. DEINOVE has developed a disruptive technology delving into the diversity of the bacterial world for the achievement of two of the greatest societal challenges of the 21^st century: the fight against antimicrobial resistance and the transition to an organic production model for the nutrition and cosmetics industries. We innovate every day for sustainable development. We hope to continue the adventure and win the national award and we are already delighted with the recognition we have received during this first step," says Emmanuel PETIOT, General Manager of DEINOVE.

ABOUT DEINOVE

DEINOVE (Euronext Growth Paris: ALDEI) is a biotech company that discovers, develops and produces high added-value compounds from rare microorganisms for healthcare, nutrition and cosmetic fields. To do so, DEINOVE draws on two key assets:

a unique library of 6,000 rare or unexploited bacterial strains;
a metabolic and fermentation engineering platform capable of leveraging these natural "micro-factories" to turn them into new industrial standards.